Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Literature DB >> 22249187

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Carmel Pezaro¹, Gerhardt Attard.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2012 PMID： 22249187 DOI： 10.1038/nrurol.2011.235

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

8 in total

1. Beyond hormone therapy for prostate cancer with PARP inhibitors.

Authors: Johann Sebastian de Bono; Shahneen Sandhu; Gerhardt Attard
Journal: Cancer Cell Date: 2011-05-17 Impact factor: 31.743

2. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors: J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal: Cancer Cell Date: 2011-05-17 Impact factor: 31.743

3. Abiraterone and increased survival in metastatic prostate cancer.

Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245

4. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors: Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal: Lancet Date: 2011-02-25 Impact factor: 79.321

5. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors: David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal: Cancer Cell Date: 2011-05-27 Impact factor: 31.743

Review 6. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.

Authors: Gerhardt Attard; Johann S de Bono
Journal: Clin Cancer Res Date: 2011-06-15 Impact factor: 12.531

7. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.

Authors: Y Wang; T Romigh; X He; M-H Tan; M S Orloff; R H Silverman; W D Heston; C Eng
Journal: Oncogene Date: 2011-05-02 Impact factor: 9.867

8. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal: Cancer Cell Date: 2011-05-17 Impact factor: 31.743

8 in total

1. Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

Authors: Bo Li; Wenfu Lu; Zhenbang Chen
Journal: Receptors Clin Investig Date: 2014

2. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.

Authors: Xin-Qi Pei; Da-Lin He; Ge Tian; Wei Lv; Yu-Mei Jiang; Da-Peng Wu; Jin-Hai Fan; Kai-Jie Wu
Journal: Int Urol Nephrol Date: 2017-02-04 Impact factor: 2.370

3. Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis.

Authors: Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Ning Jiang; Zhiqun Shang; Yuanjie Niu
Journal: Cancer Manag Res Date: 2018-09-17 Impact factor: 3.989

8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.

Authors: Kai-Jie Wu; Xin-Qi Pei; Ge Tian; Da-Peng Wu; Jin-Hai Fan; Yu-Mei Jiang; Da-Lin He
Journal: Asian J Androl Date: 2018 Mar-Apr Impact factor: 3.285

8 in total

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

1. Beyond hormone therapy for prostate cancer with PARP inhibitors.

2. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

3. Abiraterone and increased survival in metastatic prostate cancer.

4. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

5. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Review 6. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.

7. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.

8. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

1. Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

2. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.

3. Neutrophil-lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis.

4. Visceral disease in castration-resistant prostate cancer.

5. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Review 6. The emerging role of histone lysine demethylases in prostate cancer.

7. Complete regression of advanced prostate cancer for ten years: A case report and review of the literature.

8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.